Ocuphire Pharma Investor Day Presentation Deck

P VEGA-1 Study Design Assessed Nyxol Alone Efficacy Nyxol as Single Drop vs. Placebo Met Pre-Specified Endpoints in the Trial VEGA-1 Phase 2 Trial 17 US sites 150 Presbyopic patients 90 Visit 1 Screening/Baseline 0.75% Nyxol Nyxol or Placebo Placebo *3-4 daily evening doses and then visit 2 on Day 5 Source: VEGA-1 Study Design N=73 Nyxol (N=43) Nyxol (N=30) ~8PM Evening Dosing 4 days N=74 Placebo (N=31) Placebo (N=43) 12 Hrs LDP Drop 0 min No Treatment ~8AM Assessments for Nyxol Alone & Placebo LDP Drop No Treatment Visit 2 (Day 5) Nyxol + LDP (N=43) Primary Endpoint Nyxol (N=30) 30min 1 Hr 2 Hr 3 Hr 4 Hr 6 Hr Placebo (N=31) 18 Hrs Post-dose Placebo (N=43) ** Nyxol alone evaluated 12 hours post dosing Ocuphire PHARMA

View entire presentation